Accuray Names Paul Miele Chief Commercial Officer

Accuray ( (ARAY) ) has issued an announcement.

On April 6, 2026, Accuray appointed veteran medical-technology executive Paul Miele as Senior Vice President and Chief Commercial Officer, adding him to its executive leadership team to lead the global commercial organization. With nearly two decades of experience turning around and scaling capital equipment businesses at Johnson & Johnson MedTech, Globus Medical and Intuitive Surgical, Miele will oversee Accuray’s global commercialization strategy across sales, marketing, pricing, market access and partnerships, a move aimed at boosting commercial execution, driving growth in systems and services, and supporting the company’s ongoing business transformation.

Accuray’s leadership highlighted Miele’s track record in rebuilding commercial operating models, reactivating installed bases and accelerating capital equipment and services revenue, including reversing revenue declines and delivering double-digit annual sales growth in his prior role. The appointment underscores Accuray’s push to better monetize its large installed base, expand value-added solutions and strengthen its competitive positioning in the global radiation therapy market, with potential implications for long-term value creation for customers, patients and investors as the company seeks to improve commercial performance.

The most recent analyst rating on (ARAY) stock is a Hold with a $0.32 price target. To see the full list of analyst forecasts on Accuray stock, see the ARAY Stock Forecast page.

Spark’s Take on ARAY Stock

According to Spark, TipRanks’ AI Analyst, ARAY is a Neutral.

ARAY scores low primarily due to weak financial quality (return to losses, declining revenue, and high leverage with a thin equity buffer). Technicals reinforce the risk with a strong downtrend below key moving averages and negative MACD. The latest earnings call further pressures the outlook with reduced revenue/EBITDA guidance and margin deterioration, despite supportive demand indicators (book-to-bill and backlog) and ongoing cost-reduction initiatives.

To see Spark’s full report on ARAY stock, click here.

More about Accuray

Accuray Incorporated is a Madison, Wis.-based medical technology company that develops and manufactures radiation therapy systems for cancer treatment, including solutions for oncology and neuro-radiosurgery. The company focuses on innovative, market-changing platforms designed to treat complex cases and streamline care for more common indications, serving clinicians and patients in more than 70 countries worldwide.

Average Trading Volume: 1,162,570

Technical Sentiment Signal: Sell

Current Market Cap: $49.33M

Learn more about ARAY stock on TipRanks’ Stock Analysis page.